Memantin Starterpackung Abz

Memantine, the active ingredient in Memantin Starterpackung Abz, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of Alzheimer’s disease in patients with moderate to severe cognitive impairment.

GNH USA supplies Memantin Starterpackung Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease.

Alzheimer's disease: improves cognition, daily functioning, and global clinical status in patients with moderate to severe disease.

Memantine may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmia - Severe hepatic injury - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal ideation or behavior - Psychosis or severe agitation

When prescribing memantine, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required in patients with reduced renal function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiovascular disease: observe blood pressure and heart rate, especially in hypertensive patients. - Concomitant NMDA antagonists: avoid additive neuro‑excitatory effects. - Pregnancy: safety category unknown; use only if potential benefit justifies potential risk. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantine can interact with other medicines that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid): - Amantadine or other NMDA antagonists: additive neuro‑pharmacologic effects may increase toxicity. - Strong CYP450 inducers (e.g., rifampin, carbamazepine): may reduce memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): monitor for changes in efficacy. - Diuretics: watch for alterations in blood pressure. - CNS depressants (e.g., benzodiazepines): may enhance sedation or dizziness.